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volume leads to reduced wall tension, aims to restore the
normal mass/volume ratio, and has been proposed as a
treatment modality for heart failure resulting from dilated
cardiomyopathy.5-7 Although early data have been
encouraging, with improvement of LV function and rever-
sal of congestive heart failure, patient outcomes have been
variable, different surgical techniques have been used, and
long-term survival and prolonged beneficial effects have
yet to be evaluated.6,8-12 Furthermore, patient selection
criteria remain unclear.13-15
The Cleveland Clinic, therefore, prospectively evalu-
ated this operation as a surgical option for patients with
advanced heart failure resulting from dilated cardiomy-
opathy. In the initial publication from that series, we
made several positive observations, including acute
improvement in LV function, mitral regurgitation, and
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clinical functional class during early follow-up (mean 5
months).8 We also noted, however, the occurrence of
unpredictable early failures (22%) and concluded that
the operation warranted investigation, but not wide-
spread dissemination, as an alternative to transplanta-
tion until several issues were studied.8,16 Those issues
included long-term durability, the role of associated
mitral valve repair, and risk factors that could be useful
to determine candidate selection. 
The purpose of this article is to assess the later effects
of PLV in terms of (1) clinical time-related outcomes,
(2) factors predictive of these outcomes with specific
attention to the influence of preoperative mitral regur-
gitation, and (3) assessment of the durability of acute
improvement in LV function and mitral valve compe-
tence.
Patients and methods
Patients. Sixty-two patients (76% male; 54 ± 14 years,
range 17-72 years) underwent PLV between May 1996 and
December 1998. All patients were in New York Heart
Association functional class III (38%) or IV (62%). All but 3
were transplant candidates and listed as United Network for
Organ Sharing status 1 (n = 23) or status 2 (n = 36). Inotropic
support preoperatively included inotropic agents in 23
patients, intra-aortic balloon counterpulsation in 3 patients,
and an LV assist device (LVAD) in 1 patient (HeartMate
LVAD; Thermo Cardiosystems, Inc, Woburn, Mass).
Patient selection was based on the hypothesis that patients
with dilated cardiomyopathy without extensive areas of scar
would benefit from the procedure.8 An LV end-diastolic
dimension (LVEDD) of more than 7.0 cm as determined by
echocardiography was a prerequisite. All but 3 patients were
evaluated and accepted as transplant candidates should
mechanical circulatory support or cardiac transplantation be
necessary after the PLV surgery.
Informed consent was obtained from all patients after ver-
bal and written discussion of risks, alternatives, and perceived
benefits of the operation were discussed by the cardiologists,
surgeon, and other members of the heart failure/transplant
team. The 62 patients were chosen from approximately 3000
referrals. Most often patients were turned down for medical
reasons or because the patient was too well, but other patients
refused PLV after informed consent discussions and contin-
ued toward transplantation or with medical therapy. Patients
were reviewed at the weekly heart failure/transplant team
meeting as part of the Kaufman Center for Heart Failure. The
Cleveland Clinic Institutional Review Board was notified of
this prospective study and reviewed and approved protocols
regarding blood samples for neurohormones and a study of
amiodarone use.
At the time of preoperative evaluation all patients had heart
failure. Only patients with heart failure of at least 6 months’
duration were eligible (range 6-240 months). All patients
referred for surgery were evaluated by at least one heart fail-
ure cardiologist from The Cleveland Clinic Foundation and
had been optimized with medical therapy. Medications at the
time of surgery in the 62 patients were angiotensin-convert-
ing enzyme inhibitor, 47 (76%); β-blocker, 10 (16%); digital-
is, 45 (73%); loop diuretic, 50 (81%); metolazone, 6 (10%);
amiodarone, 10 (16%); dobutamine or milrinone, 23 (37%);
and warfarin, 16 (26%).
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Table I. Variables considered in risk analysis
Preop
Baseline Evaluation In operating room
Demographic Clinical status Hemodynamics Hemodynamics Operative Postop
Age, BSA, Duration of HF,
sex, race preop inotropes
LV function
0-4+ MR
BSA, Body surface area; HF, heart failure; BP, blood pressure; MVO2, oxygen consumption; HR, heart rate; CO, cardiac output; LV, left ventricular; PAP, pulmonary
artery pressure; CI, cardiac index; RAP, right atrial pressure; LAP, left atrial pressure; MV, mitral valve; TV, tricuspid valve; LVEF, left ventricular ejection fraction;
LVEDV, left ventricular end-diastolic volume; MR, mitral regurgitation; SV, stroke volume; LVEDD, left ventricular end-diastolic diameter.
BP (diastolic, systolic, mean
[mm Hg]), exercise maxi-
mum MVO2 (mL · min–1 ·
kg–1), HR (beats/min), CO 
(L · min–1 · m–2), indexed LV
internal diameter (mm/m2)
LV function
LVEF, LVEDV (mL), LV inter-
nal diameter (mm), indexed
LVEDV (mL/m2), indexed
LV internal diameter
(mm/m2), 0-4+ MR
BP (diastolic, systolic, mean
[mm Hg]), PAP (diastolic,
systolic, mean [mm Hg]),
HR (beats/min), CO
(L/min), CI (L · min–1 ·
m–2), RAP, LAP (mm Hg)
LV function
LVEF, LVEDV (mL), LV
diameter (mm), indexed
LVEDV (mL/m2), indexed
LV internal diameter
(mm/m2), 0-4+ MR, SV
Papillary resection (ante-
rior, posterior), MV
annuloplasty with ring,
TV repair, LV mass
resected (g)
LV function
LVEF, LVEDV (mL), LV
internal diameter (mm),
indexed LVEDV
(mL/m2), indexed LV
internal diameter
(mm/m2), differences in
preop and postop mea-
sures of LVEDV and
LVEDD
Optimal medical therapy for heart failure was reinstituted
as soon as possible after surgery, including angiotensin-
converting enzyme inhibitors, diuretics, digoxin, and amio-
darone.7,8 β-Blockers, including carvedilol, were added as
tolerated. Beginning in 1997 implantable defibrillators were
implanted for most patients before hospital discharge.
Surgical technique. The surgical technique used is a modifi-
cation of that originally described by Batista and associates6
and has been published earlier.8 In brief, a wedge-shaped por-
tion of the left ventricle supplied by the circumflex artery was
resected. If possible, the papillary muscles were left intact (n =
29; 47%), but if needed to obtain normal LVEDD, one or both
papillary muscles were resected and transferred to an adjoining
site on the ventricular wall (n = 33; 53%). A mitral annuloplas-
ty was performed using the Cosgrove-Edwards annuloplasty
system (Baxter Healthcare Corp, Edwards Division, Irvine,
Calif). In addition, the free edges of the anterior and posterior
mitral leaflets were approximated (Alfieri stitch). Due to resid-
ual 2+ mitral regurgitation at the end of the operation, 2 patients
underwent intraoperative mitral valve replacement. Papillary
muscle resection and reimplantation was performed as
described8 in 33 patients (53%); 10 of them (16% of total cases)
had both anterior and posterior resections, 3 had only anterior
resection, and 20 had only posterior resection. Concomitant sur-
gical procedures included tricuspid valve repair (36 patients),
coronary artery bypass grafting (5 patients), and aortic valve
repair (1 patient). 
Time-related outcomes 
End points. The end points were (1) all cause mortality, (2)
implantation of an LVAD, (3) return to class IV heart failure
(including relisting for transplantation), (4) use of an
implantable defibrillator, and (5) the earliest of these end
points (event-free survival).
Clinical follow-up. None of the patients were lost to fol-
low-up, which was performed at The Cleveland Clinic when-
ever possible. Patients were asked to return to The Cleveland
Clinic at 3, 6, and 12 months and annually thereafter. Because
many patients resided far away, they were not always able to
return. Patients unable to return for follow-up were contacted
by telephone for determination of clinical events and func-
tional capacity. Referring physicians were also contacted for
follow-up, including echocardiograms and functional studies. 
Mean follow-up was 24 ± 12 months and encompasses 76
patient-years. The longest follow-up extends to 3.5 years.
Among surviving patients, 10% have been followed up for 3
or more years, 73% have been followed up for 2 or more
years, and 94% for more than 1 year.
Time-related estimates and their predictors. Non-
parametric estimates of outcomes were obtained by the
method of Kaplan and Meier.17 A parametric method was
used to resolve the number of phases of instantaneous risks of
each event (hazard function) and to estimate their shaping
parameters.18
The multivariable analyses of outcomes were preceded
by exploratory analysis of the variables in Table I, includ-
ing correlation analysis, stratified life-table analyses, and
decile risk analysis of ordinal and continuous variables to
determine possible transformations of scale needed to cal-
ibrate properly the variables to each outcome. Among the
potential risk factors screened were several measurements
obtained across time preoperatively for each patient,
including hemodynamic measures and echocardiographic
LV function. In addition, echocardiographic assessments
of mitral valve regurgitation required incorporation with an
analysis of a time-varying covariable. Thereafter, multi-
variable analyses were performed sequentially, first con-
sidering baseline and demographic variables, then preoper-
ative measures, then immediate postoperative measures,
and finally, the sequence of postoperative estimates of
mitral valve regurgitation. The analysis used a directed
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Fig 1.  Time-related survival after PLV. Also shown in the figure is the hazard function analysis for risk of death
depicted enlarged for clarification (scale is 0%-25%). Numbers within parentheses represent patients.
technique of entry of variables into the multivariable
model.19 The P value criterion for retention of variables in
the final models was .1. 
Durability of acute LV improvement. Serial echocardio-
graphic measurements, hemodynamics, and clinical assessment
were performed immediately preoperatively, immediately post-
operatively, 3, 6, 12 months, and annually postoperatively in
survivors. Intraoperative transesophageal echocardiography
was obtained from all patients with HP Sonos 5.0/3.7-MHz
probes with an HP Sonos 1500/2500 echocardiography
machine (Hewlett-Packard Company, Palo Alto, Calif). LV
dimensions and volumes were quantified using the disks from
the apical 4-chamber view. The amount of mitral valve regur-
gitation was assessed qualitatively using a categorical grade
from 0 (none) to +4 (severe). 
LV ejection fraction (LVEF), LVEDD, LV end-diastolic
volume index (LVEDVI), and mitral valve regurgitation
grade were analyzed by longitudinal data analysis method.20
A random coefficients model was fitted to the repeated mea-
sures to quantify postoperative time trends (Proc mixed in
SAS; SAS Institute, Inc, Cary, NC). For the analysis of mitral
regurgitation, we used longitudinal repeated-measures mod-
eling for ordinal categorical variables (Proc GenMod in
SAS), assuming a multinomial distribution with an ordinal
logistic characteristic (link function). All these analyses used
the exact time of assessment and all available data, although
they were truncated in patients at the time of death, trans-
plantation, or follow-up.
Presentation. Mean values are presented ± 1 SD.
Confidence levels (CL) for proportions are 68%, corre-
sponding to 1 SE. Nomograms were constructed by solving
each multivariable equation for freedom from each event at
3 years. 
Results
Time-related outcomes 
Survival. There were 2 hospital deaths (3.2%, CL
1.0%-7.5%). Survival was 99%, 80%, and 60% at 30
days, 1 year, and 3 years (Fig 1). This included 3
patients who died after transplantation; thus, survival
before transplantation was 99%, 82%, and 64% at 30
days, 1 year, and 3 years. The risk of death (hazard
function) consisted of two phases, an early phase that
peaked after about 4 months (with a risk of approxi-
mately 6%/month) and a constant hazard phase of
1.2%/month that merged with the early hazard phase
by 12 months (Fig 1). Mode of death included heart
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Fig 2. Time-related freedom from implantation of LVAD after PLV. Numbers within parentheses represent patients.
Also shown in the figure is the hazard-function analysis for risk of LVAD implantation, depicted enlarged for clar-
ification (scale is 0%-25%).
Table II. Predictors of time related outcomes
Risk factors Coefficient ± SD P value
Death 0.083 ± 0.023 .0004
Increasing PAP at evaluation (systolic)
LVAD* 0.083 ± 0.023 .006
Decreasing exercise maximum MVO2†
Return to class IV –1.61 ± 0.59 .0002
Decreasing exercise maximum MVO2‡
Event-free survival 0.89 ± 0.24 .008
Increasing preoperative mean LAP§
PAP, Pulmonary artery pressure; LVAD, left ventricular assist device; MVO2,
oxygen consumption; LAP, left atrial pressure.
*Early-phase risk factor (all other events contain late-phase risk factors).
†Natural logarithmic transformation.
‡Inverse transformation.
§Natural logarithmic transformation.
failure/arrhythmias (11 patients), unwitnessed sudden
death (4 patients), multiorgan failure (4 patients, 1 after
transplantation), and stroke, witnessed cardiac arrest,
and acute rejection (1 patient each). 
LVAD. Eleven patients (18%, CL 13%-24%) received
an LVAD as rescue therapy. Of these, 2 died of multi-
organ failure, 8 received a heart transplant, and 1 was
removed from LVAD support after LV recovery (this
patient was in New York Heart Association class III
after 3 years). Freedom from LVAD was 85%, 83%,
and 82% after surgery at 30 days, 1 year, and 3 years
(Fig 2). The hazard function rapidly declined after a
peak of 1.8%/month at 30 days after surgery (Fig 2).
Class IV heart failure. Thirty-two patients returned to
class IV heart failure. Freedom from class IV failure
was 81%, 57%, and 42% at 30 days, 1 year, and 3 years
(Fig 3). The hazard function rapidly declined from a
peak of 8.4%/month at 30 days postoperatively, giving
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Fig 3. Time-related freedom from return to functional class IV heart failure after PLV. Also shown in the figure is
the hazard-function analysis for risk of return to class IV heart failure, depicted enlarged for clarification (scale is
0%-25%). Numbers within parentheses represent patients.
Fig 4. Time-related freedom from composite events (defined as death, relisting for transplantation, implantation of
LVAD, or return to class IV heart failure) after PLV. Also shown in the figure is the hazard-function analysis for
risk of composite events, depicted enlarged for clarification (scale is 0%-25%). Numbers within parentheses rep-
resent patients.
way to a slightly increasing hazard of 1% to
1.9%/month between 12 and 36 months (Fig 3).
Event-free survival. Event-free survival was 80%, 49%,
and 26% at 30 days, 1 year, and 3 years (Fig 4). The haz-
ard function revealed a rapidly declining early phase with
a risk of 8.6%/month at 30 days, which merged with a
slightly declining late phase between 3.3% and
2.2%/month at 12 to 36 months of follow-up (Fig 4).
Predictors. For each time-related outcome, a single
predictor was identified (Table II). Increased pul-
monary artery systolic pressure (beyond 40 mm Hg) at
evaluation was a powerful predictor of poor survival
(Fig 5). Reduced maximum exercise oxygen consump-
tion at baseline was associated with a rapid return to
class IV heart failure (Fig 6). The higher the left atrial
pressure, the lower the event-free survival (Fig 7).
Preoperative mitral valve regurgitation was not a risk
factor for any post-PLV outcome (Figs 8 and 9). When
follow-up time-related echocardiographic assessment
of postoperative mitral valve regurgitation was consid-
ered, it was found unlikely to be related to death (coef-
ficient 0.39 ± 0.35; P = .3), return of class IV heart fail-
ure (coefficient –0.017 ± 0.27; P = .5), or event-free
survival (coefficient 0.24 ± 0.22; P = .3). Furthermore,
no significant risk with respect to survival, return to
class IV heart failure, or the composite late event was
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Fig 5.  Nomogram depicting the risk of late (at 3 years) death in relation to increased systolic pulmonary artery
(PA) pressure.
Fig 6.  Nomogram depicting the risk of late (at 3 years) return to class IV heart failure in relation to decreased max-
imum exercise oxygen consumption.
associated with the resection and reimplantation of
anterior, posterior, or both papillary muscles.
Durability of acute LV improvement. PLV reduced
the LVEDD immediately preoperatively compared
with immediately postoperatively (from 8.4 ± 1.1 cm to
5.92 ± 0.8 cm; P = .01) and the LVEDVI (from 133 ±
48.6 mL to 64.1 ± 26 mL; P < .0001) while it increased
the LVEF (16 ± 7.6 to 31.5 ± 10.9; P < .0001). Late
changes in the LVEDD, LVEDVI, and function were
also examined to determine the degree of redilatation
and subsequent impact, if any, on LVEF. Analysis of
both LVEDD and LVEDVI postoperatively demon-
strated a small but steady trend toward redilatation and
increase in volumes (Figs 10 and 11), and late LVEF
showed a small but steady decline (Fig 12, Table III). 
The proportion of patients with no mitral valve regur-
gitation declined between operation and the 3-month
assessment, giving rise to an increased number of
patients with 1+ regurgitation and, to a lesser extent, an
increased number with 2+ regurgitation (Tables IV and
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Fig 7. Nomogram depicting the risk of late (at 3 years) composite events in relation to increased mean left atrial
pressure (PLA).
Fig 8. Influence of preoperative mitral regurgitation on survival after PLV. The patients were divided into 2 groups;
1 group with mitral regurgitation grade 0, 1+, or 2, and 1 group of patients with mitral regurgitation grade 3+ or 4+.
Note the lack of significance between the groups (P = .7).
V and Fig 13). However, 3+ mitral regurgitation devel-
oped in only 1 patient, and this was the patient with
valvular cardiomyopathy. He also had worsening LV
function and a high pulmonary vascular resistance. He
received a transplant but died of right ventricular dys-
function. None of the patients had MR that was judged
to be related to papillary muscle reimplantation.
Automatic implantable cardioverter/defibrillators.
Of the 62 patients, 28 had implantable cardioverter/
defibrillators, including 7 who had the device preop-
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Fig 9. Influence of preoperative mitral regurgitation on event-free survival after PLV. The patients were divided into
2 groups: 1 group with mitral regurgitation grade 0, 1+, or 2, and 1 group of patients with mitral regurgitation grade
3+ or 4+. There was a tendency, although nonsignificant, for a difference between the 2 groups of patients (P = .1).
Fig 10. Change in end-diastolic diameter across time. Each gray line represents values for a single patient. Pre
equals the immediate pre-PLV value and time 0 is the immediate post-PLV value. The dotted line connects the
median value pre-PLV with the mean predicted value immediately after PLV. One heavy line is the average time
trend representing the so-called fixed-effects portion of the longitudinal data model.
eratively. During follow-up, 10 patients had ventricu-
lar arrhythmias treated by the implantable cardio-
verter/defibrillator: 2 of the 7 (29%) with preopera-
tive devices and 8 of 21 (38%) with postoperative
devices. 
Discussion
Principal findings. In the present study we have
demonstrated that PLV for dilated cardiomyopathy is
associated with a significant early failure rate and
event-free survival at 3 years of only 26%. Furthermore,
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Fig 11. Change in end-diastolic volume index across time. Each gray line represents values for a single patient. Pre
equals the immediate pre-PLV value and time 0 is the immediate post-PLV value. The dotted line connects the
median value before PLV with the mean predicted value immediately after PLV. One heavy line is the average time
trend representing the so-called fixed effects portion of the longitudinal data model.
Fig 12. Change in ejection fraction across time. Each gray line represents values for a single patient. Pre equals the
immediate pre-PLV value and time 0 is the immediate post-PLV value. The dotted line connects the median value
before PLV with the mean predicted value immediately after PLV. One heavy line is the average time trend repre-
senting the so-called fixed-effects portion of the longitudinal data model.
some risk factors for failure have been determined, and
the lack of correlation between preoperative mitral
regurgitation and clinical outcome has been estab-
lished. With rare exceptions, late failure was not asso-
ciated with redilation, drop in LVEF, or return of mitral
regurgitation even for patients with papillary muscle
resection.
We observed 80% survival at 1 year, which com-
pares favorably with survival reported from other
centers.6,9-11,21 However, since the freedom from com-
posite events at the same time was only 49%, this indi-
cates that the aggressive use of LVADs and transplanta-
tion accounts for this seemingly high survival at 1 year.
This is corroborated by the fact that 3-year overall sur-
vival was only 60%. It should also be emphasized that
varying patient selection and surgical techniques make
comparison between centers difficult. Other centers
have combined the outcomes for idiopathic dilated car-
diomyopathy with patients who underwent PLV for
ischemic cardiomyopathy. We excluded our patients
with ischemic cardiomyopathy, because reconstruction
for ischemic disease has a long history and a much
more predictable beneficial effect than does PLV for
idiopathic disease.22,23 Also, unlike others, we did not
think it was adequate to simply report survival and,
therefore, sought to determine whether patients were
significantly improved by creating the composite event
for failure, but not necessarily fatal events. 
Although the failure rate was high after PLV, a num-
ber of event-free survivors had improvement in subjec-
tive clinical status and objective measurements (maxi-
mum exercise oxygen consumption) even though
overall ventricular function was not restored to normal
and cardiac output changes were modest.7,8 These
patients did benefit from PLV, and multivariate analy-
sis to assess risk factors has given some insight into the
predictors of poor outcome. Earlier analysis based on
our smaller patient population with shorter follow-up
could only reveal young age and preoperative diastolic
function to be risk factors for failure.13,24 It was further
recognized that these younger patients represented a
more severely diseased patient population with higher
pulmonary artery pressure and a higher requirement for
inotropic support.13 On the basis of the present group
of patients and follow-up, we were able to identify fur-
ther preoperative risk factors including increased sys-
tolic pulmonary artery pressure, decreased maximum
exercise oxygen consumption, and increased left atrial
pressure. Presumably, PLV in patients without these
risk factors will increase the 26% subgroup of patients
who were alive and well in late follow-up. Emergency
surgery,21 preoperative poor ventricular compliance (ie,
diastolic dysfunction),24 increased myocardial cell
diameter,14,25 and a left dominant coronary artery sys-
tem26 are other suggested risk factors for failure. We
did not have the tissue analyzed for myocardial cell
diameter and, therefore, cannot comment.
The reduction in LV wall stress quantified by echocar-
diography and magnetic resonance imaging scans and
the improvement in LV systolic function may be offset
by a reduction in compliance.24,27-29 Computer modeling
and finite element analysis indicate that the reduction in
LV diastolic function will blunt the improvement in
myocardial efficiency.29,30 We have clues that suggest
that reduced compliance at baseline may contribute to
poorer late outcomes, that is, higher pulmonary artery
and left atrial pressures in this study, higher pulmonary
artery pressures in young patients in the prior study,13
and compliance function derived from pressure-area
loops.24 Also, late exercise hemodynamics after PLV
showed a significant increase in cardiac index with exer-
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Table III. Factors associated with increasing LV mea-
sures
Factors* Coefficient ± SD P value
LVEF
Higher LVEF evaluation 0.51 ± 0.17 .006
Decrease across time† –1.57 ± 0.28 <.0001
Indexed LVEDV
Increase across time‡ 0.029 ± 0.005 <.0001
LVEDD
Increase across time§ 0.009 ± 0.002 .0003
LV, Left ventricular; SD, standard deviation; LVEF, left ventricular ejection
fraction; LVEDV, left ventricular end-diastolic volume; LVEDD, left ventricu-
lar end-diastolic dimension.
*In all cases, the larger the value immediately preceding PLV, the larger the
change across time of follow-up.
†Natural logarithmic transformation of time.
‡Interaction term between indexed end-diastolic volume at evaluation and nat-
ural logarithmic transformation of time (months).
§Interaction term between end-diastolic dimension at evaluation and natural
logarithmic transformation of time (months). 
Table IV. Parameter estimates for longitudinal model
of mitral valve regurgitation progression across time
Parameter Estimate ± SD P
Months after PLV* –0.43 ± 0.090 <.0001
Intercepts†
1 (Grades 0 vs > 0) 1.03 ± 0.25 <.0001
2 (Grades ≤ 1 vs > 1) 2.6 ± 0.38 <.0001
3 (Grades ≤ 2 vs 3) 5.2 ± 1.02 <.0001
SD, Standard deviation; PLV, partial left ventriculectomy.
*In [months] natural logarithmic transformation.
†Intercepts for each grade change.
cise (2.2 ± 0.5 to 3.8 ± 1.6; P = .0077), but a marked
increase in pulmonary artery pressures (pulmonary
artery systolic 52 ± 20 mm Hg to 79 ± 17 mm Hg; P =
.0001: pulmonary artery mean 36 ± 12 mm Hg to 52 ±
10 mm Hg; P = .0003), also suggesting abnormal com-
pliance.31 We postulate, but cannot absolutely confirm
with this small group of patients, that stiff fibrotic hearts
are very prone to failure with this operation. To treat
these patients without transplantation will require a pro-
cedure that decreases wall stress and improves systolic
function and myocardial efficiency without impairing
diastolic function. Devices in development may bring us
much closer to this goal.32-35
The influence of mitral valve repair per se in PLV is
of interest. Indeed, it has been shown that mitral valve
repair can reverse LV remodeling and dysfunction in
patients with dilated or ischemic cardiomyopathy com-
bined with severe (4+) mitral regurgitation.36-38 It
should be emphasized, though, that in the present
patient population (as with most cardiomyopathy
patients), the mitral regurgitation was generally less
severe. Furthermore, multivariate analysis of risk fac-
tors could not distinguish any favorable effects of PLV
and mitral valve repair in patients with preoperative
moderately severe (3+) or severe (4+) mitral regurgita-
tion in relation to patients with mild (1+) to moderate
(2+) mitral regurgitation. If anything, there was a ten-
dency toward a worse outcome for patients with preop-
erative mitral regurgitation grades 3 to 4 (P = .1). This
is also supported by reports on the isolated positive
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Table V. Progression of mitral  valve regurgitation
Time
Baseline 1 wk 3 mo 12 mo 24 mo
Regurgitation grade No % No % No % No % No %
0 1 2 34 81 20 53 11 61 6 43
1+ 3 5 6 14 11 29 5 28 6 43
2+ 12 20 2 5 6 16 2 11 2 14
3+ 24 40 0 0 1 3 0 0 0 0
4+ 20 33 0 0 0 0 0 0 0 0
Total 60 100 42 100 38 100 18 100 14 100
Fig 13. Change in mitral valve regurgitation across time. Each symbol represents a grade of mitral regurgitation for
various grades as time progresses, using the actual trend of regurgitation within each patient, only crudely illus-
trated by the aggregate proportions at each time point (see Table IV). The number of observations of grade was 56,
38, 18, and 14 immediately postoperatively, and at 3, 12, and 24 months, respectively. 
effect of PLV, without mitral valve reconstruction, in
patients with dilated cardiomyopathy lacking mitral
regurgitation.39,40 However, to maintain the beneficial
effects of PLV, we thought it was important to prevent
the return of mitral regurgitation and redilatation of the
left ventricle.8,12 Therefore, we were very aggressive
with valve repair to avoid chronic volume overload that
we thought might lead to late redilatation and failure.
There was a slight increase in the mitral regurgitation
during follow-up, but 4+ regurgitation did not develop
in any patient and 3+ regurgitation developed in only 1
patient. Mitral regurgitation after surgery was not asso-
ciated with clinical failure. Whether the repair held up
due to the small annuloplasty ring, the Alfieri repair, or
the reconstruction of the left ventricle that reduced api-
cal displacement of the papillary musles cannot be
determined from this study.
This study answered several other questions about
the late effects of PLV.41 Late redilatation was unusual
and, therefore, was not the cause of failure. The mod-
est improvement in LVEF decreased very slowly but
was not associated with failure. The incidence of sud-
den death was relatively low (n = 4) and can be avoid-
ed after this operation, in large part by the liberal use
of implantable cardioverter/defibrillators and amio-
darone. A previous study failed to show that the ven-
tricular tachycardia morphology was related to the sur-
gical scar.42
Initially there was a discussion that this operation
should be evaluated in a randomized trial versus med-
ical therapy or cardiac transplantation.7,16,39,41,43,44
We resisted this strategy for several reasons. First,
comparing the earliest “learning curve” results of this
complex operation to establishied therapies without
some preliminary experience with patient selection,
operative technique, and perioperative care seemed
premature. We pursued our strategy of a carefully
monitored prospective study to accrue information to
determine whether such a study would be warranted,
and in which patients. Second, the practical aspects
of a large multicenter clinical surgical trial were
daunting. These aspects included funding, careful
patient selection, uniform surgical technique and
postoperative care, as well as management of the
medical control population or transplant arm of the
study. We did not think this study could be contem-
plated until clinical follow-up indicated that such a
trial warranted the time and expense required.
Finally, as events unfolded, we became aware of
devices that may be applied to the same patient pop-
ulation, but with the expectation of a lower morbidi-
ty and with Food and Drug Administration oversight
of clinical trials.32-35 In this regard we think the
Batista operation may be a step along the way (like
the Vineberg operation before coronary artery
bypass) and that a prospective study is no longer war-
ranted.
Limitations of the study. This is a prospective but not
randomized study; therefore, no direct comparison to
other surgical procedures or medical therapy alone can
be made. Although this study was aimed at investigating
the impact of the surgical procedure, it was considered
important to maximize pharmacological treatment post-
operatively. Therefore, postoperative adjustment of
drugs may have contributed to some observed positive
effects. Malignant arrhythmias, which were the cause
of death in some early patients, may have been avoid-
ed by implantation of defibrillators in all patients; this
was only routinely done in later patients. Serial com-
parisons are naturally biased in that only patients
reaching follow-up are included in the analysis per-
formed. We attempted to account for this by our statis-
tical analysis of results. Nevertheless, patients whose
treatment failed early could not have values obtained
later, and some patients lived far from Cleveland and
could not return for follow-up. However, follow-up was
complete for clinical events.
Clinical inferences. In conclusion, in this pilot
study of PLV with mitral valve surgery for dilated car-
diomyopathy, we observed a 60% 3-year survival and
26% freedom from failure. Failures were largely
unpredictable from preoperative clinical studies, but
risk factors included increased left atrial and systolic
pulmonary artery pressures and decreased maximum
exercise oxygen consumption. Modest improvement
in LV systolic function was sustained and late ven-
tricular dilatation was rare. Correction of preoperative
mitral regurgitation did not account for the clinical
benefit, and some evidence indicates that worsening
diastolic function may have contributed to failures.
We infer from these observations that the Batista pro-
cedure is not a predictable reliable alternative to trans-
plantation. In other cultures and socioeconomic set-
tings this procedure may be further investigated, or in
a nontranslant population, or as an alternative to
LVADs as a “biologic” bridge-to-transplantation. In
our opinion, the experience was not a dead end, how-
ever, and may have spawned devices that can be
applied with a low morbidity to change LV shape and
improve LV function.
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Discussion
Dr Gianni Angelini (Bristol, England). I congratulate Dr
Franco-Cereceda and his colleagues for this excellent presen-
tation, which undoubtedly will shed further light on what is
still a very controversial surgical procedure. We in Bristol had
a similar experience in terms of early outcome and late fol-
low-up, the only difference being that we only operated on
patients who were not suitable for transplantation. In your
series, Dr Franco-Cereceda, it is my feeling that you made a
deliberate attempt to preserve the mitral valve. We recently
reported 2 cases in which an interpapillary resection and a
successful repair of the mitral valve required further revision
because we were unable to discontinue cardiopulmonary
bypass. After an enlarged resection and mitral valve replace-
ment, the patient did well. 
Do you think your approach may have limited in some of
your cases the extension of your resection and therefore
undermined the full potential of the surgical procedure? 
My second question relates to papillary reimplantation. I
am slightly uncomfortable about this technique. Do you think
this may have affected the long-term ventricular function and
perhaps even mitral valve competence? Since you have 2 fair-
ly large groups of patients in whom the mitral valve was
repaired, with or without implantation of the papillary mus-
cle, can you describe how these 2 groups did at late follow-up
and whether there was any difference? 
Dr Franco-Cereceda. Thank you very much, Dr Angelini,
for those remarks. The impact of mitral valve repair or
replacement in relation to the Batista procedure has attracted
a great deal of attention. It is important to realize that what we
say is not that the mitral valve repair is not beneficial for the
heart. We see, as have others, that with a postoperative return
of mitral valve regurgitation the outcome is worse. 
We could not see any real differences in outcome between
patients undergoing resection of the papillary muscle and
those with an intact papillary muscle. The subvalvular appa-
ratus is important for survival in general in mitral valve regur-
gitation, and preservation of the valve is important to obtain
the best possible results, because there will always be some
changes in the geometry when the papillary muscles are
removed. Basically, all patients received an annuloplasty sys-
tem and the Alfieri stitch. 
As shown in the figures, there is no redilatation, indicating
that we have no return of mitral valve regurgitation, and there
are essentially no differences between the groups with and
without papillary muscle resection. 
Dr Hisayoshi Suma (Kamakura, Japan). We continue to per-
form ventriculoplasty for nonischemic dilated cardiomyopathy
and have done 68 cases in 3 years with a 2-year survival of 71%.
From this experience, we have learned that some patients with
nonischemic dilated cardiomyopathy have a bad septum and a
relatively intact lateral wall, which is detectable on intraopera-
tive echocardiography. The ordinary Batista procedure could be
dangerous in such cases, so we have used endoventricular
anteroseptal patch plasty in 9 patients. 
Have you found that the extent of myocardial damage in
nonischemic dilated cardiomyopathy is not always homoge-
neous and some surgical modification is necessary when the
weakest part is located in the septum? 
Dr Franco-Cereceda. Thank you, Dr Suma, for your
remarks and your question. We know of the very elegant stud-
ies performed by you and your colleagues in Japan. What we
have been trying to do is resect the lateral wall and, if need-
ed, the posterior wall, but I am sure that modifications of the
procedure can be done. Such modifications would definitely
include patching of the septum. We have not been doing that,
and we do not anticipate any more of these operations, so I
cannot comment more than that. 
Dr O. Howard Frazier (Houston, Tex). In July of 1996, at
about the same time this procedure was started in Cleveland,
we did our first case. The patient was severely ill with class
IV disease and remains well in class I nearly 4 years later.
However, our long-term results in general reflect what was so
ably presented here. A comparison of our results with those
of a nontransplant center in Belgrade, Yugoslavia, though,
revealed a very interesting correlation between myocyte
diameter and relatively good results, which they experienced,
as well as duration of heart failure. This may simply mean
that the favorable outcomes may be more reflective in the less
ill patients, as I think your data seemed to support—patients
with better myocardial oxygen consumptions and low pul-
monary pressures. Yet 26% of your patients remain out of
class IV. Do you think it could be an alternative to transplan-
tation in a properly selected group? 
Dr Franco-Cereceda. Thank you, Dr Frazier, for your
remarks and your question. First, let me comment on your
studies on myocyte sites and fibrosis. Your suggestion of a
histologic classification system regarding these procedures is
a very intriguing one. We know of your excellent results, and
we also know that you, in comparison with the Belgrade
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group, have been looking at the different reasons for the dif-
ferences in outcome. 
With regard to your question, I think you are right that it is
important not to delay if you are going to operate on these
patients. It is probable that the more severe the disease, the
more unfavorable the outcome. But, as you mentioned, 26%
of our patients are event-free at 3 years’ follow-up. There is
definitely something to this operation. 
The reason that we will not use it at The Cleveland
Clinic is that we are a transplant institution. Later in this
meeting, Dr Patrick McCarthy will present some other
surgical options for these patients. We are definitely not
condemning the operation. We are merely stating that it is
unpredictable and unreliable and should be restricted to
cases not amenable to transplantation or other modes of
therapy. 
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Fig 2. Box plots of Mental Development Index scores stratified by treatment group (alpha-stat vs pH-stat) and diag-
nosis group (D-TGA, TOF/other, and VSD/CAVC). Within a box, the solid bar represents the median value, the
dashed line represents the mean value, the upper boundary of the closed box represents the 75th percentile, and the
lower boundary of the closed box represents the 25th percentile. The vertical lines extend to the 10th and 90th per-
centiles, with more extreme values plotted as diamonds
Notice of correction
In the February 2001 issue of the Journal, in the article by Bellinger and associates titled “Developmental and
Neurologic Effects of Alpha-Stat Versus pH-Stat Strategies for Deep Hypothermic Cardiopulmonary Bypass in
Infants,” (2000;121:374-83), an error was made. Fig 1 was published twice and Fig 2 was omitted. The correct ver-
sion of Fig 2 is published below, and the correct version of the article is available online at www.mosby.com/jtcvs.
